TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03754660
Drug: BAY1237592
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation with dry powder inhaler, single dose.
Study: NCT00570388
Drug: Prometa Treatment Program
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol.
Study: NCT04250636
Drug: 3BNC117-LS
Normalized name: Emcor LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3BNC117-LS at 30mg/kg
Study: NCT00887224
Drug: Desvenlafaxine succinate sustained release 50 mg
Normalized name: desvenlafaxine succinate 50 MG
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
Study: NCT00887224
Drug: Desvenlafaxine succinate sustained release 25 mg
Normalized name: desvenlafaxine succinate 25 MG
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablet for taper, once daily for 1 week
Study: NCT00887224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
Study: NCT03779672
Drug: Memantine Hydrochloride 10 mg
Normalized name: memantine hydrochloride 10 MG
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps
Study: NCT02316301
Drug: Long interval misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Study: NCT02316301
Drug: Short interval misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Study: NCT00505336
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral Eplerenone titrated to 50mg for duration of 12 months
Study: NCT01697683
Drug: Probiotic Lactobacilli
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
Study: NCT01697683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01255514
Drug: high dose dexamethsone
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
Study: NCT03516370
Drug: Saccharomyces Boulardii 250 MG
Normalized name: Saccharomyces boulardii 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
Study: NCT00743574
Drug: Medroxyprogesterone (Provera)
Normalized name: medroxyprogesterone Oral Tablet [Provera]
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg, PO, daily for ten days
Study: NCT02138994
Drug: Triple Antibiotic Ointment Neosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~* Subject may continue the application of Neosporin until wound closure or~* Subject may cross over to the treatment group for 3 months
Study: NCT01458600
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T Diclofenac 50 mg twice daily for 12 months
Study: NCT03378791
Drug: Iron bisglycinate Oral Tablet
Normalized name: ferrous bisglycinate / polysaccharide iron complex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03378791
Drug: Ferrous Fumarate Oral Tablet
Normalized name: ferrous fumarate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02413138
Drug: Somavaratan (VRS-317)
Normalized name: Prostin VR
DrugBank: Somavaratan (DB12421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting recombinant human growth hormone
Study: NCT01436175
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
Study: NCT00724126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00705406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
Study: NCT01079806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
Study: NCT01040312
Drug: CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
Study: NCT01040312
Drug: Platinum analogues
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
Study: NCT01738698
Drug: SPD489 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 40 mg once-daily for up to 12 weeks
Study: NCT01738698
Drug: SPD489 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 100 mg once-daily for up to 12 weeks
Study: NCT01738698
Drug: SPD489 160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 160 mg once-daily for up to 12 weeks
Study: NCT01738698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once-daily for 12 weeks
Study: NCT00797056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline SQ daily for 10 days
Study: NCT00252382
Drug: SNS-595 Injection
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
Study: NCT00154609
Drug: Gu-Sui-Bu (Davallia Divaricata)
Normalized name: Gu
DrugBank: Guanidine (DB00536)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00273052
Drug: Carvedilol Phosphate modified release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03043443
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Natural health product for sleep problems treatment
Study: NCT03043443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose containing pills
Study: NCT04056754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.
Study: NCT04269694
Drug: Medihoney dressing
Normalized name: MediHoney Dressing 3/4x12"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
Study: NCT02191670
Drug: METALYSE®
Approvals — FDA: no, EMA: no, PMDA: no
Description: weight-adjusted dosage as single bolus over 5 to 10 seconds
Study: NCT01263132
Drug: F0434
Approvals — FDA: no, EMA: no, PMDA: no
Description: F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
Study: NCT01375699
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As prescribed by treating provider.
Study: NCT04053270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous implant
Study: NCT00300404
Drug: daraprim
Normalized name: Daraprim
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: 7614524
Drug: Extended-release 5-ISMN
Normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release 5-ISMN 60 mg once daily
Study: 24183868
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (POCT) with paclitaxel (175 mg/m²) and cisplatin (60 mg/m²) for four cycles.
Study: 28404108
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of treatment
Study: 10455342
Drug: G-CSF treatment
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF treatment starting at day 1
Study: 8138680
Drug: E5 (edobacomab)
Normalized name: HYDROXYPROPYL METHYLCELLULOSE E5 [II]
DrugBank: Edobacomab (DB17779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5 (edobacomab) 1 mg/kg and 4 mg/kg
Study: 15271690
Drug: Testosterone injections
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone injections + No training
Study: 9455517
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin prophylaxis (500 mg/week)
Study: 14726744
Drug: Immunoglobulin (Ig)
Normalized name: FUSION PROTEIN COMPOSED OF 3 BINDING DOMAINS CONSISTING OF THREE-ALPHA-HELIX MOTIFS, EACH DERIVED FROM THE IMMUNOGLOBULIN (IG)-BINDING Z-DOMAIN OF STAPHYLOCOCCAL PROTEIN A (SPA), ENGINEERED FOR BINDING TO TWO HOMODIMER SUBUNITS OF HUMAN INTERLEUKIN 17A (
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin (Ig) therapy
Study: 20883991
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone analogue (GnRH-a; gosareline acetate; Zoladex)
Study: 31870139
Drug: Biosimilar monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosimilar monoclonal antibodies awareness
Study: 2957052
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 1 g daily
Study: 8277950
Drug: High sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High sucrose diet (5600 +/- 2100 mg/kg/day)
Study: 8277950
Drug: Low sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low sucrose diet with aspartame (38 +/- 13 mg/kg/day)
Study: 17634183
Drug: Budesonide as
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide as needed (identical treatment to group 1 during months 1‐6, then budesonide for exacerbations as needed for months 7‐18)
Study: 20937044
Drug: Mesalamine granules
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine granules (MG) 1.5 g once-daily
Study: 15452681
Drug: Isradipine with
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine with low dose methamphetamine (15 mg)
Study: 1677625
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal tablets and PGE2 vaginal pessaries
Study: 11932561
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH) treatment
Study: 1513972
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy using portable liquid oxygen systems
Study: 24632279
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES) treatment in patients with DM and type B2/C lesions
Study: 18451188
Drug: Nefiracetam 900
Normalized name: Nefiracetam
DrugBank: Nefiracetam (DB13082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefiracetam 900 mg
Study: 16098636
Drug: RIX4414 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 vaccine (104.7, 105.2 or 105.8 ffu)
Study: 19502645
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy alone
Study: 15346657
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment
Study: 17984738
Drug: PEG 3350
Normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 3350 laxative
Study: 23097311
Drug: SC abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SC abatacept (125 mg/week) without methotrexate (monotherapy)
Study: 23097311
Drug: Long-term extension
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term extension (LTE) with SC abatacept and methotrexate (combination)
Study: 6337618
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% cream
Study: 29472356
Drug: 6-gene signature
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6-gene signature related to B-cell receptor pathway
Study: 8529776
Drug: Loperamide oxide
Normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide oxide (2 mg initially, then 1 mg after each unformed stool, mean daily dose 2.7 mg)
Study: 12935434
Drug: Amoxicilina 500
Normalized name: Amoxicilina
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicilina 500 mg capsules
Study: 19813463
Drug: Piroxicam patch
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam patch vs Piroxicam cream (intermediate visit, day 4)
Study: 1415377
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r‐HuEPO) treatment at Hb 12 g/dl
Study: 30589600
Drug: Degarelix 240
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 240 mg (day 1 of cycle 1) then 80 mg (day 1 of cycles 2-6) plus letrozole 2.5 mg/day
Study: 7957521
Drug: Intravenous colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous colchicine (elderly subjects)
Study: 27829249
Drug: Decoy receptor
Normalized name: NF-kappaB Decoy
DrugBank: NF-kappaB Decoy (DB05559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoy receptor 3 (DcR3)
Study: 16181608
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise therapy
Study: 24837064
Drug: Hypnotic Analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic Analgesia (HA)
Study: 31886828
Drug: Petrolatum intranasal
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum intranasal ointment and nonmedicated soap cloths (placebo)
Study: 29588972
Drug: Lacosamide 400
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide 400 mg/day
Study: 16632815
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron (4 mg)
Study: 25914474
Drug: Lamivudine (LAM)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (LAM) 100 mg daily for 48 weeks
Study: 19169651
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) therapy initiated within 24 hours of surgery
Study: 19169651
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) therapy continued
Study: 11515348
Drug: Lansoprazole intact
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole intact capsule (30 mg orally)
Study: 19939872
Drug: Org 26828
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 26828 at doses higher than 1 μg/kg
Study: 19939872
Drug: Org 26828
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 26828 at doses up to 0.3 μg/kg
Study: 10963459
Drug: Oral ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ascorbate treatment; specific dosage and duration not mentioned.
Study: 22123096
Drug: Oral 9-THC
Normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 9-THC maintenance
Study: 25803777
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 50 mg in 10 cc, self-administered 3 times daily at meal times
Study: 2143593
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (360 micrograms total, 60 micrograms into each nostril, repeated twice at 15 min intervals)
Study: 9389922
Drug: Granisetron plus
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron plus dexamethasone (20 mg i.v.)
Study: 26892135
Drug: Icosabutate 600
Normalized name: Ethyl icosapentate
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosabutate 600 mg once daily
Study: 20863419
Drug: Control tablet
Normalized name: Daily-Vite Weight Control Tablet
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control tablet administered twice a day.
Study: 11553203
Drug: Post-prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-prandial insulin lispro (PL)
Study: 28982159
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for hypertension
Study: 7985893
Drug: Cerezyme (imiglucerase)
Normalized name: imiglucerase Injection [Cerezyme]
DrugBank: Imiglucerase (DB00053)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cerezyme (imiglucerase) infused every 2 weeks for 9 months at a dose of 60 U/kg body weight
Study: 24090538
Drug: Nurse-administered educational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered educational intervention about MRSA prevention
Study: 26853953
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy (IMT) alone